Nurix Therapeutics (NASDAQ:NRIX) Now Covered by Analysts at Robert W. Baird

Analysts at Robert W. Baird started coverage on shares of Nurix Therapeutics (NASDAQ:NRIX) in a research report issued on Friday, StockNewsAPI reports. The brokerage set an “outperform” rating and a $26.00 price target on the stock. Robert W. Baird’s target price would indicate a potential upside of 6.38% from the company’s previous close.

NRIX has been the subject of a number of other reports. Needham & Company LLC dropped their price objective on shares of Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, July 12th. Oppenheimer lifted their price target on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday. Stifel Nicolaus reaffirmed a “buy” rating and set a $27.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, May 15th. Royal Bank of Canada lifted their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Friday, July 12th. Finally, Truist Financial initiated coverage on shares of Nurix Therapeutics in a report on Wednesday, July 31st. They set a “buy” rating and a $36.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.00.

Nurix Therapeutics Stock Performance

NRIX opened at $24.44 on Friday. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -8.37 and a beta of 2.23. The company has a fifty day moving average of $22.11 and a 200 day moving average of $17.28. Nurix Therapeutics has a fifty-two week low of $4.22 and a fifty-two week high of $26.12.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.08). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The company had revenue of $12.09 million for the quarter, compared to analysts’ expectations of $19.35 million. On average, equities research analysts forecast that Nurix Therapeutics will post -2.95 earnings per share for the current year.

Insider Activity

In other news, CFO Houte Hans Van sold 2,490 shares of Nurix Therapeutics stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $51,468.30. Following the transaction, the chief financial officer now owns 54,479 shares of the company’s stock, valued at approximately $1,126,080.93. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Nurix Therapeutics news, insider Christine Ring sold 1,900 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $17.01, for a total transaction of $32,319.00. Following the sale, the insider now owns 19,838 shares of the company’s stock, valued at approximately $337,444.38. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 2,490 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $51,468.30. Following the sale, the chief financial officer now directly owns 54,479 shares in the company, valued at approximately $1,126,080.93. The disclosure for this sale can be found here. In the last quarter, insiders sold 61,715 shares of company stock worth $1,449,070. 7.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Nurix Therapeutics

Large investors have recently made changes to their positions in the business. Massachusetts Financial Services Co. MA boosted its holdings in shares of Nurix Therapeutics by 248.2% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 142,146 shares of the company’s stock valued at $1,467,000 after acquiring an additional 101,320 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in shares of Nurix Therapeutics by 176.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock valued at $7,122,000 after acquiring an additional 440,112 shares during the last quarter. Trexquant Investment LP lifted its stake in shares of Nurix Therapeutics by 80.9% in the 4th quarter. Trexquant Investment LP now owns 159,318 shares of the company’s stock valued at $1,644,000 after purchasing an additional 71,252 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Nurix Therapeutics by 576.7% in the 1st quarter. Acadian Asset Management LLC now owns 160,293 shares of the company’s stock valued at $2,355,000 after purchasing an additional 136,606 shares during the period. Finally, SG Americas Securities LLC lifted its stake in shares of Nurix Therapeutics by 365.0% in the 2nd quarter. SG Americas Securities LLC now owns 103,199 shares of the company’s stock valued at $2,154,000 after purchasing an additional 81,005 shares during the period.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.